Search
depemokimab
Indications:
- eosinophilic asthma (FDA_approved) [3]
- chronic rhinosinusitis with nasal polyps
Dosage:
- 100 mg subcutaneously twice yearly
Mechanism of action:
- binds to & inhibits interleukin-5
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
References
- Jackson DJ et al
Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype.
N Engl J Med 2024. Sept 9
PMID: 39248309
https://www.nejm.org/doi/full/10.1056/NEJMoa2406673
- Gevaert P et al.
Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with
nasal polyps (ANCHOR-1 and ANCHOR-2): Phase 3, randomised, double-blind, parallel trials.
Lancet 2025 Feb 28; [e-pub].
PMID: 40037388
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00197-7/abstract
- Phend C
First Twice-Yearly Biologic Approved for Severe Eosinophilic Asthma.
Ultra-long-acting depemokimab offers potential for better uptake
MedPage Today. December 17, 2025
https://www.medpagetoday.com/allergyimmunology/asthma/119054